MARKET

LCTX

LCTX

Lineage Cell Therapeutics Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

1.210
+0.030
+2.54%
Closed 16:00 10/28 EDT
OPEN
1.190
PREV CLOSE
1.180
HIGH
1.230
LOW
1.160
VOLUME
773.29K
TURNOVER
--
52 WEEK HIGH
1.670
52 WEEK LOW
0.5339
MARKET CAP
181.48M
P/E (TTM)
-5.0459
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
What Type Of Shareholders Make Up Lineage Cell Therapeutics, Inc.'s (NYSEMKT:LCTX) Share Registry?
The big shareholder groups in Lineage Cell Therapeutics, Inc. (NYSEMKT:LCTX) have power over the company. Insiders...
Simply Wall St. · 1d ago
SNBR, GRFS among premarket gainers
SPI Energy (SPI) +56% on entering agreement with Shaanxi Tongjia Automobile.Anavex Life Sciences (AVXL) +36% after completing mid-stage study of lead drug in rare brain development disorder.Organogenesis Holdings (ORGO) +27% on Q3 preliminary results.Huttig Building Products
Seekingalpha · 10/15 12:24
OpRegen Data Update to Be Featured in Presentation by Christopher D. Riemann, MD at 2020 American Academy of Ophthalmology Meeting
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated interim results from a Phase 1/2a study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), will be presented at the 2020 American Academy of Ophthalmology Annual Meeting (AAO 2020), to be held virtually (November 13-15, 2020). The presentation, "Phase 1/2a Study of Subretinally Transplanted hESC-Derived RPE Cells in Advanced Dry-Form AMD Patients" will be featured as part of the Original Paper Session, OP02V Retina, Vitreous Original Papers on November 15, 2020 between 7:40am to 8:25am Pacific Time by Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute (CEI) and University of Cincinnati School of Medicine. (abstract number 30063541). In addition, data from Lineage will be shown in a presentation by Allen C. Ho, M.D. FACS, Wills Eye Hospital Attending Surgeon and Director of Retina Research, Professor of Ophthalmology, Thomas Jefferson University, entitled: "Cell Based Therapies and Surgical Strategies for Atrophic Age-Related Macular Degeneration 2020," which is being presented as part of the AAO 2020 Retina Subspecialty Day, on November 13, 2020 at 1:38pm Eastern Time.
Business Wire · 10/15 12:00
Lineage Cell Therapeutics and Cancer Research UK Announce Encouraging Preliminary Phase 1 Study Results With VAC2 for the Treatment of Non-small Cell Lung Cancer
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, and Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research, today announced encouraging preliminary results from an ongoing Phase 1 clinical study of VAC2 in non-small cell lung cancer (NSCLC). VAC2 demonstrated remarkably potent induction of immune responses in all patients dosed to date, with high levels of peripheral antigen-specific immunogenicity observed at multiple time points and confirmed by multimer staining. On the basis of these findings, and following completion of the ongoing VAC2 clinical study in NSCLC, Lineage will seek to evaluate VAC2 in combination with therapies considered biologically complementary to VAC2, such as chemotherapy and the immune cell protectant properties offered by anti-PD1 immunotherapy.
Business Wire · 10/13 14:00
Lineage Cell's VAC2 vaccine shows positive action in early-stage lung cancer study
Preliminary results from ongoing Phase 1 study of Lineage Cell Therapeutics's ([[LCTX]]) VAC2 in non-small cell lung cancer, demonstrated potent induction of immune responses in all patients dosed to date, with high
Seekingalpha · 10/13 13:32
Lineage Cell Therapeutics And Cancer Research UK Announce Preliminary Phase 1 Study Results With VAC2 For The Treatment Of Non-Small Cell Lung Cancer
Potent Induction of Immune Responses Observed with VAC2 Vaccine Peripheral Antigen-specific Immunogenicity Above 3% Observed at Multiple Timepoints VAC2 Appears Well Tolerated with No Unexpected Adverse
Benzinga · 10/13 13:10
Lineage Cell Therapeutics to Present at FORCE Wealth Virtual Fireside Chat on September 23, 2020
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, and Brandi L. Roberts, Chief Financial Officer, will be participating in a FORCE
Business Wire · 09/17 13:00
Rockwell Medical Announces Appointment of Russell L. Skibsted as Executive Vice President, Chief Financial Officer and Chief Business Officer
WIXOM, Mich., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced
GlobeNewswire · 09/15 12:59
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LCTX. Analyze the recent business situations of Lineage Cell Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LCTX stock price target is 4.800 with a high estimate of 7.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 118
Institutional Holdings: 66.40M
% Owned: 44.27%
Shares Outstanding: 149.98M
TypeInstitutionsShares
Increased
29
919.96K
New
11
1.63M
Decreased
26
988.89K
Sold Out
19
1.29M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Director
Alfred Kingsley
Chief Executive Officer/Director
Brian Culley
Chief Financial Officer
Brandi Roberts
Senior Vice President
Gary Hogge
General Counsel/Secretary
Chase Leavitt
Independent Director
Deborah Andrews
Independent Director
Don Bailey
Independent Director
Neal Bradsher
Independent Director
Stephen Farrell
Independent Director
Michael Mulroy
Independent Director
Angus Russell
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About LCTX
Lineage Cell Therapeutics, Inc., formerly BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Company is focused on developing cell therapies. It programs are based on its cell-based therapy platform. It is focused on developing treatments for conditions, including age-related degenerative diseases and other serious medical conditions. Its pipeline includes OpRegen, OPC1 and VAC2. OpRegen product candidate is a cell replacement therapy. OpRegen is comprised of retinal pigment epithelium cells and is being tested for the treatment of advanced dry age-related macular degeneration (dry AMD) with geographic atrophy. OPC1 is a cell replacement therapy comprised of oligodendrocyte progenitor cells. OPC1 is being developed for the treatment of acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy comprised of mature, antigen-presenting dendritic cells. VAC2 is being developed for non-small cell lung cancer (NSCLC).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Lineage Cell Therapeutics Inc stock information, including AMEX:LCTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LCTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LCTX stock methods without spending real money on the virtual paper trading platform.